These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 25824857)

  • 1. Predictors of postoperative morbidity after cytoreduction for advanced ovarian cancer: Analysis and management of complications in upper abdominal surgery.
    Benedetti Panici P; Di Donato V; Fischetti M; Casorelli A; Perniola G; Musella A; Marchetti C; Palaia I; Berloco P; Muzii L
    Gynecol Oncol; 2015 Jun; 137(3):406-11. PubMed ID: 25824857
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The incidence of major complications after the performance of extensive upper abdominal surgical procedures during primary cytoreduction of advanced ovarian, tubal, and peritoneal carcinomas.
    Chi DS; Zivanovic O; Levinson KL; Kolev V; Huh J; Dottino J; Gardner GJ; Leitao MM; Levine DA; Sonoda Y; Abu-Rustum NR; Brown CL; Barakat RR
    Gynecol Oncol; 2010 Oct; 119(1):38-42. PubMed ID: 20609464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The parameters to estimate postoperative severe complications classified through Clavien-Dindo after upper abdominal surgery in patients with primary and recurrent ovarian cancer.
    Yalcin Y; Tatar B; Erdemoglu E; Erdemoglu E
    Ginekol Pol; 2019; 90(10):557-564. PubMed ID: 31686411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer.
    Eisenhauer EL; Abu-Rustum NR; Sonoda Y; Levine DA; Poynor EA; Aghajanian C; Jarnagin WR; DeMatteo RP; D'Angelica MI; Barakat RR; Chi DS
    Gynecol Oncol; 2006 Dec; 103(3):1083-90. PubMed ID: 16890277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Upper abdominal surgery in advanced and recurrent ovarian cancer: role of diaphragmatic surgery.
    Fanfani F; Fagotti A; Gallotta V; Ercoli A; Pacelli F; Costantini B; Vizzielli G; Margariti PA; Garganese G; Scambia G
    Gynecol Oncol; 2010 Mar; 116(3):497-501. PubMed ID: 20004958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The benefits of low anterior en bloc resection as part of cytoreductive surgery for advanced primary and recurrent epithelial ovarian cancer patients outweigh morbidity concerns.
    Park JY; Seo SS; Kang S; Lee KB; Lim SY; Choi HS; Park SY
    Gynecol Oncol; 2006 Dec; 103(3):977-84. PubMed ID: 16837030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer.
    Bristow RE; Montz FJ; Lagasse LD; Leuchter RS; Karlan BY
    Gynecol Oncol; 1999 Mar; 72(3):278-87. PubMed ID: 10053096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of morbidity associated with pancreatic resection during cytoreductive surgery for epithelial ovarian cancer: A systematic review.
    Di Donato V; Bardhi E; Tramontano L; Capomacchia FM; Palaia I; Perniola G; Plotti F; Angioli R; Giancotti A; Muzii L; Panici PB
    Eur J Surg Oncol; 2020 Apr; 46(4 Pt A):694-702. PubMed ID: 31806515
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hematogenous Splenic Metastases as an Independent Negative Prognosis Factor at the Moment of Primary Cytoreduction in Advanced Stage Epithelial Ovarian Cancer--A Single Center Experience.
    Bacalbasa N; Balescu I; Dima S; Brasoveanu V; Popescu I
    Anticancer Res; 2015 Oct; 35(10):5649-54. PubMed ID: 26408738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PROFAST: A randomised trial implementing enhanced recovery after surgery for highcomplexity advanced ovarian cancer surgery.
    Sánchez-Iglesias JL; Carbonell-Socias M; Pérez-Benavente MA; Monreal Clua S; Manrique-Muñoz S; García Gorriz M; Burgos-Peláez R; Segurola Gurrutxaga H; Pamies Serrano M; Pilar Gutiérrez-Barceló MD; Serrano-Castro S; Balcells-Farré MT; Pérez-Barragán C; Scaillet-Houberechts A; Cossio-Gil Y; Gil-Moreno A
    Eur J Cancer; 2020 Sep; 136():149-158. PubMed ID: 32688208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Complications of radical surgery for advanced ovarian cancer].
    Chéreau E; Ballester M; Lesieur B; Selle F; Coutant C; Rouzier R; Daraï E
    Gynecol Obstet Fertil; 2011 Jan; 39(1):21-7. PubMed ID: 21183387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diaphragmatic Surgery in Advanced Ovarian, Tubal and Peritoneal Cancer. A 7-Year Retrospective Analysis of the Tumor Bank Ovarian Cancer Network.
    Muallem MZ; Almuheimid J; Richter R; Braicu EI; Osman S; Sehouli J
    Anticancer Res; 2016 Sep; 36(9):4707-13. PubMed ID: 27630317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Post-operative pancreatic fistula following splenectomy with or without distal pancreatectomy at cytoreductive surgery in advanced ovarian cancer.
    Bizzarri N; Korompelis P; Ghirardi V; O'Donnell RL; Rundle S; Naik R
    Int J Gynecol Cancer; 2020 Jul; 30(7):1043-1051. PubMed ID: 32546641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship among surgical complexity, short-term morbidity, and overall survival in primary surgery for advanced ovarian cancer.
    Aletti GD; Dowdy SC; Podratz KC; Cliby WA
    Am J Obstet Gynecol; 2007 Dec; 197(6):676.e1-7. PubMed ID: 18060979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A collaborative surgical approach to upper and lower abdominal cytoreductive surgery in ovarian cancer.
    Eng OS; Raoof M; Blakely AM; Yu X; Lee SJ; Han ES; Wakabayashi MT; Yuh B; Lee B; Dellinger TH
    J Surg Oncol; 2018 Jul; 118(1):121-126. PubMed ID: 29878375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diaphragmatic surgery during primary debulking in 89 patients with stage IIIB-IV epithelial ovarian cancer.
    Tsolakidis D; Amant F; Van Gorp T; Leunen K; Neven P; Vergote I
    Gynecol Oncol; 2010 Mar; 116(3):489-96. PubMed ID: 19954825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radical surgery versus standard surgery for primary cytoreduction of bulky stage IIIC and IV ovarian cancer: an observational study.
    Ren Y; Jiang R; Yin S; You C; Liu D; Cheng X; Tang J; Zang R
    BMC Cancer; 2015 Aug; 15():583. PubMed ID: 26268818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach.
    Chi DS; Franklin CC; Levine DA; Akselrod F; Sabbatini P; Jarnagin WR; DeMatteo R; Poynor EA; Abu-Rustum NR; Barakat RR
    Gynecol Oncol; 2004 Sep; 94(3):650-4. PubMed ID: 15350354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Postoperative morbidities after modified posterior pelvic exenteration for ovarian cancer].
    Emin L; Meeus P; Beurrier F; Ferraioli D; Carrabin N; Ray-Coquard I; Treilleux I; Chopin N
    Gynecol Obstet Fertil; 2015 May; 43(5):342-7. PubMed ID: 25899113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of Diaphragmatic Surgery as Part of Cytoreductive Effort in Advanced Stage Ovarian Cancer.
    Bacalbasa N; Balescu I; Balalau C; Ionescu O; Stoica C
    In Vivo; 2018; 32(2):431-436. PubMed ID: 29475933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.